Indie Asset Partners LLC trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 8.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,671 shares of the company’s stock after selling 262 shares during the quarter. Indie Asset Partners LLC’s holdings in Merck & Co., Inc. were worth $218,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Catalyst Private Wealth LLC acquired a new stake in shares of Merck & Co., Inc. during the third quarter valued at about $25,000. Flagship Private Wealth LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $27,000. Financial Avengers Inc. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $28,000. Joseph P. Lucia & Associates LLC acquired a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $29,000. Finally, Fiduciary Planning LLC acquired a new position in Merck & Co., Inc. in the third quarter valued at approximately $32,000. 72.86% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have issued reports on MRK. Mizuho reissued a “buy” rating and issued a $100.00 price target on shares of Merck & Co., Inc. in a research note on Sunday, December 6th. SVB Leerink boosted their price target on Merck & Co., Inc. from $100.00 to $103.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Sanford C. Bernstein reissued an “outperform” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a research note on Tuesday, November 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Merck & Co., Inc. in a report on Friday, February 5th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $95.36.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Wednesday, February 3rd. The company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.06). The business had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.65 billion. Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.16 EPS. Equities analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 7th. Shareholders of record on Monday, March 15th will be paid a $0.65 dividend. The ex-dividend date of this dividend is Friday, March 12th. This represents a $2.60 dividend on an annualized basis and a yield of 3.47%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.10%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products.
Read More: How is inflation measured?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.